169 results on '"Michel ML"'
Search Results
2. Impact of the Immunogen Nature on the Immune Response against the Major HBV Antigens in an HBsAg and HLA-humanized Transgenic Mouse Model
- Author
-
Mancini-Bourgine, M, primary, Guillen, G, additional, Michel, ML, additional, and Aguilar, JC, additional
- Published
- 2014
- Full Text
- View/download PDF
3. A splicing donor site point mutation in intron 6 of the plasmin inhibitor (α2 antiplasmin) gene with heterozygous deficiency and a bleeding tendency
- Author
-
Hanss, Michel ML, primary, Farcis, Mathilde, additional, Ffrench, Patrick O, additional, de Mazancourt, Philippe, additional, and Dechavanne, Marc, additional
- Published
- 2003
- Full Text
- View/download PDF
4. Vaccination contre le SIDA : évaluation chez les primates
- Author
-
Schlienger, K, primary, Mancini, M, additional, Tiollais, P, additional, and Michel, ML, additional
- Published
- 1995
- Full Text
- View/download PDF
5. Vaccination contre l'hépatite B : perspectives et réalités
- Author
-
Michel, ML, primary
- Published
- 1991
- Full Text
- View/download PDF
6. Effect of in feed talc supplementation on broiler performance.
- Author
-
Serge SM Mallet, Patrick PD Delord, Hervé HJ Juin, and Michel ML Lessire
- Abstract
Four experiments were performed to study the effects of the addition of 1 or 2% of talc to the diets of broiler chickens compared to an unsupplemented diet and a control diet containing 5 ppm of avilamycin. Both additives improved bird performance, weight gain (W.G.) and feed conversion ratio (F.C.R.) especially when poor performances were observed for the unsupplemented control group. Overall, when all the experiments were computed together, avilamycin significantly improved bird performance (W.G. and F.C.R.) compared to the unsupplemented diet. The effect of talc was positive but lower than avilamycin. No dose effect was observed with talc. Intestinal microflora, tested in the excreta, was decreased by avilamycin but no effect was observed with talc. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
7. SYNTHESIS OF HEPATITIS B SURFACE ANTIGEN PARTICLES CONTAINING THE PRE-S REGION EXPRESSION PRODUCT
- Author
-
Michel, Ml, Pontisso, Patrizia, Sobczack, E, Malpiece, Y, Streeck, R, and Tiollais, P.
- Published
- 1985
8. SYNTHESIS IN CHO CELLS OF HEPATITIS-B SURFACE ANTIGEN PARTICLES CONTAINING THE PRE-S2 REGION EXPRESSION PRODUCT
- Author
-
Michel, Ml, Tiollais, P, Milich, Dr, Chisari, Fv, Pontisso, Patrizia, Sobzack, E, Malpiece, Y, and Streeck, Re
- Published
- 1986
9. Un vaccin recombinant contre l'hépatite B
- Author
-
Tiollais, P, primary and Michel, ML, additional
- Published
- 1988
- Full Text
- View/download PDF
10. Research in practice. St. John's wort and depression.
- Author
-
Michel ML
- Published
- 1998
11. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial
- Author
-
Eric Billaud, Marie-Josée Wendling, Georges Haour, Fabrice Carrat, Philippe Sogni, Lionel Piroth, Patrick Miailhes, David Rey, Faiza Ajana, Alexandra Rohel, Jean-Michel Molina, Cécilie Dufour, Marie-Louise Michel, Odile Launay, Le Trait d'Union, centre de soins de l'infection par le VIH [CHU Strasbourg], CHU Strasbourg, Département d'infectiologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Laboratoire de Virologie [Strasbourg], Service de Maladies Infectieuses et Tropicales [Hôpital de la Croix-Rousse - HCL], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Pathogenèse des Virus de l'Hépatite B (PVHB), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service d'hépatologie médicale [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), ANRS France Recherche Nord & sud Sida-hiv hépatites, Service des Maladies Infectieuses et Tropicales [Hôpital Gustave Dron, Tourcoing], Centre Hospitalier Gustave Dron [Tourcoing], Service des maladies infectieuses et tropicales [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Service des Maladies Infectieuses et Tropicales [CHU Saint Louis], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], CIC Cochin Pasteur (CIC 1417), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe hospitalier Broca-Université Paris Descartes - Paris 5 (UPD5)-Hôtel-Dieu-Hôpital Cochin [AP-HP], Département de santé publique [AP-HP Groupe Hospitalier Est Parisien], Hôpitaux universitaires Est parisien [AP-HP], French National Institute for Medical Research (Inserm)., French National Agency for Research on AIDS and Viral Hepatitis (ANRS)., ANRS HB04 B-BOOST study group : Aumaitre H, Berger JL, Devidas A, Abgrall S, Patey O, Thiebaut MC, Lucht F, Hoen B, Lascoux-Combe C, Lortholary O, Delcey V, De Truchis P, Jeantils V, Vittecoq D, Slama L, Zucman D, Levy Y, Katlama C, Simon A, Girard PM, Molina JM, Pierre-Francois S, Chennebault JM, Le Berre R, Neau D, Livrozet JM, Poizot-Martin I, Matheron S, Reynes J, Billaud É, Perre P, Durand J, Rosenthal É, Arvieux C, Cuzin L, Verdon R, Leclercq P, Ajana F, May T, Debab Y, Lefort A, Delacroix I, Beck-Wirth G, Poinsignon Y, Prazuck T, Philibert P, Viard JP, Andrieu M, Rey D, Carrat F, Launay O, Piroth L, Miailhes P, Ajana F, Sogni P, Michel ML, Wendling MJ, Rohel A, Dufour C, Bailly F, Hanslik T, Touze E, Pol S, Aboulker JP, Chaix ML, Gougeon ML, Allain L, Kaabeche K, Simony M, Rohel A, Metro A, Diallo A, Mendy Y, Paul C, Carrat F, van der Vliet D, Martin K, Pouget N, Dorival C, Dufour C, Rabiéga P, Bendriss R, Lutton O, Duflos Y, N'Diaye A, Boinet S, Toubiwou E, Madouni A, Kutala C, Chevallot C, Goderel I, Pourteau V, Quimbert S, Pannetier G, Bitchiné S, Sallé AV, Chau F., Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Université Paris Descartes - Paris 5 (UPD5)-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM), and Lissalde, Claire
- Subjects
Male ,Pediatrics ,efficacy ,HIV Infections ,Booster dose ,law.invention ,0302 clinical medicine ,Randomized controlled trial ,law ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,vaccine ,Single-Blind Method ,030212 general & internal medicine ,Vaccines, Synthetic ,0303 health sciences ,number ,infected patient ,Middle Aged ,Hepatitis B ,3. Good health ,Vaccination ,Treatment Outcome ,Infectious Diseases ,homosexual man ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Female ,France ,Viral hepatitis ,Adult ,medicine.medical_specialty ,Hepatitis B vaccine ,Immunization, Secondary ,virus ,Young Adult ,03 medical and health sciences ,medicine ,Humans ,Hepatitis B Vaccines ,Hepatitis B Antibodies ,Aged ,Intention-to-treat analysis ,030306 microbiology ,business.industry ,medicine.disease ,rate ,Regimen ,injection ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business ,impaired response - Abstract
Equipe CHU UB (EA) Pôle MERS CT3 Hors Enjeu ANRS HB04 B-BOOST study group : Hugues Aumaitre (Centre Hospitalier Marechal Joff re, Perpignan, France); Jean-Luc Berger (Centre Hospitalier Universitaire de Reims– Hopital Robert Debre, Reims, France); Alain Devidas (Hopital Gilles de Corbeil–Centre Hospitalier Sud Francilien, Corbeil Essonne, France); Sophie Abgrall (Centre Hospitalier Universitaire Avicenne, Avicenne, France); Olivier Patey (Centre Hospitalier Intercommunal de Villeneuve St Georges, Villeneuve Saint Georges, France); Marie-Christine Drobacheff Thiebaut (Centre Hospitalier Universitaire de Besancon–Hopital Saint Jacques, Besancon, France); Frederic Lucht (Centre Hospitalier Universitaire de St Etienne–Hopital Nord, Saint Etienne, France); Bruno Hoen (Centre Hospitalier Universitaire de Besancon–Hopital Saint Jacques, Besancon, France); Caroline Lascoux-Combe (Hopital Saint Louis, Paris, France); Olivier Lortholary (Hopital Necker, Paris, France); Veronique Delcey (Hopital Lariboisiere, Paris, France); Pierre De Truchis (Hopital Raymond–Poincare, Garches, France); Vincent Jeantils (Hopital Jean Verdier, Bondy, France); Daniel Vittecoq (Le Kremlin Bicetre, France); Laurence Slama (Hopital Tenon, Paris, France); David Zucman (Hopital Foch, Suresnes, France); Yves Levy (Hopital Henri Mondor, Creteil, France); Christine Katlama (Hopital Pitie Salpetriere, Paris, France); Anne Simon (Hopital Pitie Salpetriere, Paris, France); Pierre-Marie Girard (Hopital Saint Antoine, Paris, France); Jean-Michel Molina (CISIH, Hopital Saint Louis, Paris, France); Sandrine Pierre-Francois (Centre Hospitalier Universitaire de Fort de France–Hopital Pierre Zobda Quitman, Fort de France, France); Jean-Marie Chennebault (Centre Hospitalier Universitaire d’Angers–Hopital de l’Hotel Dieu, Angers, France); Rozenn Le Berre (Centre Hospitalier Universitaire de Brest– Hopital de La Cavale Blanche, Brest, France); Didier Neau (Hopital Pellegrin, Bordeaux, France); Jean Michel Livrozet (Hopital Edouard Herriot, Lyon, France); Isabelle Poizot-Martin (Hopital Sainte Marguerite, Marseille, France); Sophie Matheron (Hopital Bichat, Paris, France); Jacques Reynes (Hopital Gui De Chauliac, Montpellier, France); Eric Billaud (Centre Hospitalier Universitaire de Nantes–Hotel Dieu, Nantes, France); Philippe Perre (Centre Hospitalier Departemental de Vendee–Les Oudairies, La Roche sur Yon, France); Jacques Durand (Centre Hospitalier Universitaire de Nice–Hopital de l’Archet, Nice, France); Eric Rosenthal (Centre Hospitalier Universitaire de Nice–Hopital de l’Archet, Nice, France); Cedric Arvieux (Centre Hospitalier Universitaire de Rennes–Hopital Pontchaillou, Rennes, France); Lize Cuzin (Centre Hospitalier Universitaire de Toulouse–Hopital Purpan, Toulouse, France); Renaud Verdon (Centre Hospitalier Universitaire Cote de Nacre, Caen, France); Pascale Leclercq (Centre Hospitalier Universitaire de Grenoble–Hopital Albert Michallon, Grenoble, France); Faiza Ajana (Hopital Gustave Dron, Tourcoing, France); Thierry May (Centre Hospitalier Universitaire Nancy–Hopital Brabois, Nancy, France); Yasmine Debab (Centre Hospitalier Universitaire de Rouen–Hopital Charles Nicolle, Rouen, France); Agnes Lefort (Hopital Beaujon, Clichy, France); Isabelle Delacroix (Centre Hospitalier Intercommunal de Creteil, Creteil, France); Genevieve Beck-Wirth (Hopital du Moenchberg, Mulhouse, France); Yves Poinsignon (Centre Hospitalier Bretagne-Atlantique Vannes, Vannes, France); Thierry Prazuck (Centre Hospitalier Regional–Hopital de La Source, Orleans, France); Patrick Philibert (Hopital Europeen Marseille, Marseille, France); Jean-Paul Viard (Hopital Hotel Dieu, Paris, France).; International audience; BACKGROUND:Revaccination with double-dose hepatitis B vaccine has been recommended in HIV-infected patients who do not respond to standard vaccination, but has not yet been assessed. We aimed to compare the safety and immunogenicity of a reinforced hepatitis B revaccination protocol with the standard revaccination schedule in HIV-infected patients not responding to primary vaccination.METHODS:We did this multicentre, open-label, randomised controlled trial, at 53 centres in France. HIV-infected adults (aged ≥18 years), with CD4 counts of 200 cells per μL or more and no response to a previous hepatitis B vaccination or a 20 μg booster dose, were randomly assigned (1:1), according to a computer-generated randomisation list with permuted blocks (block sizes of two to six), to receive either standard-dose (20 μg) or double-dose (40 μg) recombinant hepatitis B vaccine at weeks 0, 4, and 24. Randomisation was stratified by baseline CD4 count (200-349 vs ≥350 cells per μL). Patients and treating physicians were not masked to treatment allocation, but the randomisation list was concealed from the investigators who assigned participants to the vaccination groups. The primary endpoint was the proportion of responders, defined as patients with hepatitis B surface antibody (anti-HBs) titres of 10 mIU/mL or more, at week 28. We did analysis by modified intention to treat. This study is registered with ClinicalTrials.gov, number NCT00670839.FINDINGS:Between May 19, 2008, and May 8, 2011, 178 participants were randomly assigned to the standard-dose group (n=90) or the double-dose group (n=88), of whom 176 (98%) participants were included in the primary efficacy analysis. At week 28, we recorded a response in 60 patients (67%, 95% CI 57-77) in the standard-dose group versus 64 patients (74%, 63-82) in the double-dose group (p=0·334). Except for more frequent local reactions in the double-dose group than the standard-dose group (13 [15%] vs four [4%] patients; p=0·020), there was no difference in safety between groups.INTERPRETATION:In adults with HIV-1 who have not responded to previous hepatitis B vaccination, double-dose revaccination did not achieve a higher response rate than did revaccination with standard single-dose regimen. However, the safety profile was similar between treatment groups. Our results should be assessed in future studies before double-dose vaccine can be considered for the standard of care of vaccine non-responders.FUNDING:French National Institute for Medical Research-French National Agency for Research on AIDS and Viral Hepatitis.
- Published
- 2015
12. Dissecting the respective roles of microbiota and host genetics in the susceptibility of Card9 -/- mice to colitis.
- Author
-
Danne C, Lamas B, Lavelle A, Michel ML, Da Costa G, Pham HP, Lefevre A, Bridonneau C, Bredon M, Planchais J, Straube M, Emond P, Langella P, and Sokol H
- Subjects
- Animals, Mice, Mice, Knockout, Genetic Predisposition to Disease, Disease Models, Animal, Mice, Inbred C57BL, Colon microbiology, Colon metabolism, Inflammatory Bowel Diseases microbiology, Inflammatory Bowel Diseases genetics, Inflammatory Bowel Diseases immunology, Female, Male, CARD Signaling Adaptor Proteins genetics, Colitis microbiology, Colitis genetics, Colitis immunology, Gastrointestinal Microbiome, Interleukin-22, Pancreatitis-Associated Proteins genetics, Dextran Sulfate, Interleukins genetics, Interleukins metabolism
- Abstract
Background: The etiology of inflammatory bowel disease (IBD) is unclear but involves both genetics and environmental factors, including the gut microbiota. Indeed, exacerbated activation of the gastrointestinal immune system toward the gut microbiota occurs in genetically susceptible hosts and under the influence of the environment. For instance, a majority of IBD susceptibility loci lie within genes involved in immune responses, such as caspase recruitment domain member 9 (Card9). However, the relative impacts of genotype versus microbiota on colitis susceptibility in the context of CARD9 deficiency remain unknown., Results: Card9 gene directly contributes to recovery from dextran sodium sulfate (DSS)-induced colitis by inducing the colonic expression of the cytokine IL-22 and the antimicrobial peptides Reg3β and Reg3γ independently of the microbiota. On the other hand, Card9 is required for regulating the microbiota capacity to produce AhR ligands, which leads to the production of IL-22 in the colon, promoting recovery after colitis. In addition, cross-fostering experiments showed that 5 weeks after weaning, the microbiota transmitted from the nursing mother before weaning had a stronger impact on the tryptophan metabolism of the pups than the pups' own genotype., Conclusions: These results show the role of CARD9 and its effector IL-22 in mediating recovery from DSS-induced colitis in both microbiota-independent and microbiota-dependent manners. Card9 genotype modulates the microbiota metabolic capacity to produce AhR ligands, but this effect can be overridden by the implantation of a WT or "healthy" microbiota before weaning. It highlights the importance of the weaning reaction occurring between the immune system and microbiota for host metabolism and immune functions throughout life. A better understanding of the impact of genetics on microbiota metabolism is key to developing efficient therapeutic strategies for patients suffering from complex inflammatory disorders. Video Abstract., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
13. Saccharomyces boulardii CNCM I-745 supplementation during and after antibiotic treatment positively influences the bacterial gut microbiota.
- Author
-
Spatz M, Wang Y, Lapiere A, Da Costa G, Michaudel C, Danne C, Michel ML, Langella P, Sokol H, and Richard ML
- Abstract
Introduction: Antibiotic effects on gut bacteria have been widely studied, but very little is known about the consequences of such treatments on the mycobiota, the fungal part of the microbiota and how the length of administration influences both microbiota. Here, we examined the effect of antibiotics (ATB) on the composition of bacterial and fungal microbiota and how the administration of Saccharomyces boulardii CNCM I-745 influences both microbiota., Methods: In order to get closer to the human microbiota, the mice used in this study were subjected to fecal microbiota transfer (FMT) using human feces and subsequently called human microbiotaassociated (HMA) mice. These mice were then treated with amoxicillinclavulanate antibiotics and supplemented with S. boulardii during and after ATB treatment to understand the effect of the yeast probiotic on both bacterial and fungal microbiota. Bacterial and fungal microbiota analyses were done using 16S and ITS2 rRNA amplicon-based sequencing., Results: We showed that the administration of S. boulardii during ATB treatment had very limited effect on the fungal populations on the long term, once the yeast probiotic has been cleared from the gut. Concerning bacterial microbiota, S. boulardii administration allowed a better recovery of bacterial populations after the end of the ATB treatment period. Additionally, 16S and ITS2 rRNA sequence analysis revealed that 7 additional days of S. boulardii administration (17 days in total) enhanced the return of the initial bacterial equilibrium., Discussion: In this study, we provide a comprehensive analysis of how probiotic yeast administration can influence the fungal and bacterial microbiota in a model of broad-spectrum antibiotherapy., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The original study design was initially discussed between the research group and Biocodex. The decision to submit the data for publication was approved by Biocodex., (Copyright © 2023 Spatz, Wang, Lapiere, Da Costa, Michaudel, Danne, Michel, Langella, Sokol and Richard.)
- Published
- 2023
- Full Text
- View/download PDF
14. Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases.
- Author
-
Michaudel C, Danne C, Agus A, Magniez A, Aucouturier A, Spatz M, Lefevre A, Kirchgesner J, Rolhion N, Wang Y, Lavelle A, Galbert C, Da Costa G, Poirier M, Lapière A, Planchais J, Nádvorník P, Illes P, Oeuvray C, Creusot L, Michel ML, Benech N, Bourrier A, Nion-Larmurier I, Landman C, Richard ML, Emond P, Seksik P, Beaugerie L, Arguello RR, Moulin D, Mani S, Dvorák Z, Bermúdez-Humarán LG, Langella P, and Sokol H
- Subjects
- Humans, Animals, Mice, Tryptophan metabolism, Intestines, Inflammation, Inflammatory Bowel Diseases drug therapy, Colitis chemically induced, Colitis drug therapy, Colitis metabolism
- Abstract
Objective: The extent to which tryptophan (Trp) metabolism alterations explain or influence the outcome of inflammatory bowel diseases (IBDs) is still unclear. However, several Trp metabolism end-products are essential to intestinal homeostasis. Here, we investigated the role of metabolites from the kynurenine pathway., Design: Targeted quantitative metabolomics was performed in two large human IBD cohorts (1069 patients with IBD). Dextran sodium sulphate-induced colitis experiments in mice were used to evaluate effects of identified metabolites. In vitro, ex vivo and in vivo experiments were used to decipher mechanisms involved. Effects on energy metabolism were evaluated by different methods including Single Cell mEtabolism by profiling Translation inHibition., Results: In mice and humans, intestinal inflammation severity negatively correlates with the amount of xanthurenic (XANA) and kynurenic (KYNA) acids. Supplementation with XANA or KYNA decreases colitis severity through effects on intestinal epithelial cells and T cells, involving Aryl hydrocarbon Receptor (AhR) activation and the rewiring of cellular energy metabolism. Furthermore, direct modulation of the endogenous tryptophan metabolism, using the recombinant enzyme aminoadipate aminotransferase (AADAT), responsible for the generation of XANA and KYNA, was protective in rodent colitis models., Conclusion: Our study identified a new mechanism linking Trp metabolism to intestinal inflammation and IBD. Bringing back XANA and KYNA has protective effects involving AhR and the rewiring of the energy metabolism in intestinal epithelial cells and CD4
+ T cells. This study paves the way for new therapeutic strategies aiming at pharmacologically correcting its alterations in IBD by manipulating the endogenous metabolic pathway with AADAT., Competing Interests: Competing interests: HS report lecture fee, board membership, or consultancy from Carenity, AbbVie, Astellas, Danone, Ferring, Mayoly Spindler, MSD, Novartis, Roche, Tillots, Enterome, BiomX, Biose, Novartis,Takeda, Biocodex and is cofounder of Exeliom Biosciences., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2023
- Full Text
- View/download PDF
15. CARD9 in neutrophils protects from colitis and controls mitochondrial metabolism and cell survival.
- Author
-
Danne C, Michaudel C, Skerniskyte J, Planchais J, Magniez A, Agus A, Michel ML, Lamas B, Da Costa G, Spatz M, Oeuvray C, Galbert C, Poirier M, Wang Y, Lapière A, Rolhion N, Ledent T, Pionneau C, Chardonnet S, Bellvert F, Cahoreau E, Rocher A, Arguello RR, Peyssonnaux C, Louis S, Richard ML, Langella P, El-Benna J, Marteyn B, and Sokol H
- Subjects
- Mice, Animals, Neutrophils metabolism, Cell Survival, Inflammation metabolism, Mice, Knockout, Mitochondria metabolism, Dextran Sulfate toxicity, Disease Models, Animal, Mice, Inbred C57BL, CARD Signaling Adaptor Proteins metabolism, Colitis chemically induced, Colitis prevention & control, Inflammatory Bowel Diseases
- Abstract
Objectives: Inflammatory bowel disease (IBD) results from a combination of genetic predisposition, dysbiosis of the gut microbiota and environmental factors, leading to alterations in the gastrointestinal immune response and chronic inflammation. Caspase recruitment domain 9 ( Card9 ), one of the IBD susceptibility genes, has been shown to protect against intestinal inflammation and fungal infection. However, the cell types and mechanisms involved in the CARD9 protective role against inflammation remain unknown., Design: We used dextran sulfate sodium (DSS)-induced and adoptive transfer colitis models in total and conditional CARD9 knock-out mice to uncover which cell types play a role in the CARD9 protective phenotype. The impact of Card9 deletion on neutrophil function was assessed by an in vivo model of fungal infection and various functional assays, including endpoint dilution assay, apoptosis assay by flow cytometry, proteomics and real-time bioenergetic profile analysis (Seahorse)., Results: Lymphocytes are not intrinsically involved in the CARD9 protective role against colitis. CARD9 expression in neutrophils, but not in epithelial or CD11c+cells, protects against DSS-induced colitis. In the absence of CARD9, mitochondrial dysfunction increases mitochondrial reactive oxygen species production leading to the premature death of neutrophilsthrough apoptosis, especially in oxidative environment. The decreased functional neutrophils in tissues might explain the impaired containment of fungi and increased susceptibility to intestinal inflammation., Conclusion: These results provide new insight into the role of CARD9 in neutrophil mitochondrial function and its involvement in intestinal inflammation, paving the way for new therapeutic strategies targeting neutrophils., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
16. Staphylococcus epidermidis isolates from atopic or healthy skin have opposite effect on skin cells: potential implication of the AHR pathway modulation.
- Author
-
Landemaine L, Da Costa G, Fissier E, Francis C, Morand S, Verbeke J, Michel ML, Briandet R, Sokol H, Gueniche A, Bernard D, Chatel JM, Aguilar L, Langella P, Clavaud C, and Richard ML
- Subjects
- Humans, Health Promotion, Receptors, Aryl Hydrocarbon, Skin, Staphylococcus epidermidis, Dermatitis, Atopic
- Abstract
Introduction: S taphylococcus epidermidis is a commensal bacterium ubiquitously present on human skin. This species is considered as a key member of the healthy skin microbiota, involved in the defense against pathogens, modulating the immune system, and involved in wound repair. Simultaneously, S. epidermidis is the second cause of nosocomial infections and an overgrowth of S. epidermidis has been described in skin disorders such as atopic dermatitis. Diverse isolates of S. epidermidis co-exist on the skin. Elucidating the genetic and phenotypic specificities of these species in skin health and disease is key to better understand their role in various skin conditions. Additionally, the exact mechanisms by which commensals interact with host cells is partially understood. We hypothesized that S. epidermidis isolates identified from different skin origins could play distinct roles on skin differentiation and that these effects could be mediated by the aryl hydrocarbon receptor (AhR) pathway., Methods: For this purpose, a library of 12 strains originated from healthy skin (non-hyperseborrheic (NH) and hyperseborrheic (H) skin types) and disease skin (atopic (AD) skin type) was characterized at the genomic and phenotypic levels., Results and Discussion: Here we showed that strains from atopic lesional skin alter the epidermis structure of a 3D reconstructed skin model whereas strains from NH healthy skin do not. All strains from NH healthy skin induced AhR/OVOL1 path and produced high quantities of indole metabolites in co-culture with NHEK; especially indole-3-aldehyde (IAld) and indole-3-lactic acid (ILA); while AD strains did not induce AhR/OVOL1 path but its inhibitor STAT6 and produced the lowest levels of indoles as compared to the other strains. As a consequence, strains from AD skin altered the differentiation markers FLG and DSG1. The results presented here, on a library of 12 strains, showed that S. epidermidis originated from NH healthy skin and atopic skin have opposite effects on the epidermal cohesion and structure and that these differences could be linked to their capacity to produce metabolites, which in turn could activate AHR pathway. Our results on a specific library of strains provide new insights into how S. epidermidis may interact with the skin to promote health or disease., Competing Interests: Authors LL, CC, CF, SM, AG, DB and LA were employed by the company L’Oréal Research and Innovation, Aulnay-sous-Bois. JV was employed by iMEAN, Toulouse, France. L’Oréal Research and Innovation, as funder, has been involved in the decision to submit the study for publication., (Copyright © 2023 Landemaine, Da Costa, Fissier, Francis, Morand, Verbeke, Michel, Briandet, Sokol, Gueniche, Bernard, Chatel, Aguilar, Langella, Clavaud and Richard.)
- Published
- 2023
- Full Text
- View/download PDF
17. Antibiotic treatment using amoxicillin-clavulanic acid impairs gut mycobiota development through modification of the bacterial ecosystem.
- Author
-
Spatz M, Da Costa G, Ventin-Holmberg R, Planchais J, Michaudel C, Wang Y, Danne C, Lapiere A, Michel ML, Kolho KL, Langella P, Sokol H, and Richard ML
- Subjects
- Humans, Mice, Animals, Anti-Bacterial Agents pharmacology, Gastrointestinal Tract microbiology, Fungi, Bacteria genetics, Amoxicillin-Potassium Clavulanate Combination pharmacology, Microbiota
- Abstract
Background: Effects of antibiotics on gut bacteria have been widely studied, but very little is known about the consequences of such treatments on the fungal microbiota (mycobiota). It is commonly believed that fungal load increases in the gastrointestinal tract following antibiotic treatment, but better characterization is clearly needed of how antibiotics directly or indirectly affect the mycobiota and thus the entire microbiota., Design: We used samples from humans (infant cohort) and mice (conventional and human microbiota-associated mice) to study the consequences of antibiotic treatment (amoxicillin-clavulanic acid) on the intestinal microbiota. Bacterial and fungal communities were subjected to qPCR or 16S and ITS2 amplicon-based sequencing for microbiota analysis. In vitro assays further characterized bacterial-fungal interactions, with mixed cultures between specific bacteria and fungi., Results: Amoxicillin-clavulanic acid treatment triggered a decrease in the total fungal population in mouse feces, while other antibiotics had opposite effects on the fungal load. This decrease is accompanied by a total remodelling of the fungal population with the enrichment in Aspergillus, Cladosporium, and Valsa genera. In the presence of amoxicillin-clavulanic acid, microbiota analysis showed a remodeling of bacterial microbiota with an increase in specific bacteria belonging to the Enterobacteriaceae. Using in vitro assays, we isolated different Enterobacteriaceae species and explored their effect on different fungal strains. We showed that Enterobacter hormaechei was able to reduce the fungal population in vitro and in vivo through yet unknown mechanisms., Conclusions: Bacteria and fungi have strong interactions within the microbiota; hence, the perturbation initiated by an antibiotic treatment targeting the bacterial community can have complex consequences and can induce opposite alterations of the mycobiota. Interestingly, amoxicillin-clavulanic acid treatment has a deleterious effect on the fungal community, which may have been partially due to the overgrowth of specific bacterial strains with inhibiting or competing effects on fungi. This study provides new insights into the interactions between fungi and bacteria of the intestinal microbiota and might offer new strategies to modulate gut microbiota equilibrium. Video Abstract., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
18. Help from commensals: β-hex to regulate gut immunity.
- Author
-
Michel ML
- Subjects
- Intestines, Symbiosis, beta-N-Acetylhexosaminidases
- Abstract
In a recent Science issue, Bousbaine et al. (2022) identified β-N-acetylhexosaminidase, a conserved antigen expressed by commensals that drives expansion and differentiation of intestinal intra-epithelial cells and protects against gut inflammation., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
19. Effects of Five Filamentous Fungi Used in Food Processes on In Vitro and In Vivo Gut Inflammation.
- Author
-
Poirier M, Hugot C, Spatz M, Da Costa G, Lapiere A, Michaudel C, Danne C, Martin V, Langella P, Michel ML, Sokol H, Boyaval P, and Richard ML
- Abstract
Food processes use different microorganisms, from bacteria to fungi. Yeast strains have been extensively studied, especially Saccharomyces cerevisiae. However, to date, very little is known about the potential beneficial effects of molds on gut health as part of gut microbiota. We undertook a comprehensive characterization of five mold strains, Penicillium camemberti, P. nalgiovense, P. roqueforti, Fusarium domesticum, and Geotrichum candidum used in food processes, on their ability to trigger or protect intestinal inflammation using in vitro human cell models and in vivo susceptibility to sodium dextran sulfate-induced colitis. Comparison of spore adhesion to epithelial cells showed a very wide disparity in results, with F. domesticum and P. roqueforti being the two extremes, with almost no adhesion and 20% adhesion, respectively. Interaction with human immune cells showed mild pro-inflammatory properties of all Penicillium strains and no effect of the others. However, the potential anti-inflammatory abilities detected for G. candidum in vitro were not confirmed in vivo after oral gavage to mice before and during induced colitis. According to the different series of experiments carried out in this study, the impact of the spores of these molds used in food production is limited, with no specific beneficial or harmful effect on the gut.
- Published
- 2022
- Full Text
- View/download PDF
20. Deletion of both Dectin-1 and Dectin-2 affects the bacterial but not fungal gut microbiota and susceptibility to colitis in mice.
- Author
-
Wang Y, Spatz M, Da Costa G, Michaudel C, Lapiere A, Danne C, Agus A, Michel ML, Netea MG, Langella P, Sokol H, and Richard ML
- Subjects
- Animals, Bacteria genetics, Dextran Sulfate adverse effects, Disease Models, Animal, Inflammation, Lectins, C-Type metabolism, Mice, Mice, Inbred C57BL, Colitis, Gastrointestinal Microbiome, Mycobiome
- Abstract
Background: Innate immunity genes have been reported to affect susceptibility to inflammatory bowel diseases (IBDs) and colitis in mice. Dectin-1, a receptor for fungal cell wall β-glucans, has been clearly implicated in gut microbiota modulation and modification of the susceptibility to gut inflammation. Here, we explored the role of Dectin-1 and Dectin-2 (another receptor for fungal cell wall molecules) deficiency in intestinal inflammation., Design: Susceptibility to dextran sodium sulfate (DSS)-induced colitis was assessed in wild-type, Dectin-1 knockout (KO), Dectin-2KO, and double Dectin-1KO and Dectin-2KO (D-1/2KO) mice. Inflammation severity, as well as bacterial and fungal microbiota compositions, was monitored., Results: While deletion of Dectin-1 or Dectin-2 did not have a strong effect on DSS-induced colitis, double deletion of Dectin-1 and Dectin-2 significantly protected the mice from colitis. The protection was largely mediated by the gut microbiota, as demonstrated by fecal transfer experiments. Treatment of D-1/2KO mice with opportunistic fungal pathogens or antifungal agents did not affect the protection against gut inflammation, suggesting that the fungal microbiota had no role in the protective phenotype. Amplicon-based microbiota analysis of the fecal bacterial and fungal microbiota of D-1/2KO mice confirmed the absence of changes in the mycobiota but strong modification of the bacterial microbiota. We showed that bacteria from the Lachnospiraceae family were at least partly involved in this protection and that treatment with Blautia hansenii was enough to recapitulate the protection., Conclusions: Deletion of both the Dectin-1 and Dectin-2 receptors triggered a global shift in the microbial gut environment, affecting, surprisingly, mainly the bacterial population and driving protective effects in colitis. Members of the Lachnospiraceae family seem to play a central role in this protection. These findings provide new insights into the role of the Dectin receptors, which have been described to date as affecting only the fungal population, in intestinal physiopathology and in IBD. Video Abstract., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
21. Route of Sensitization to Peanut Influences Immune Cell Recruitment at Various Mucosal Sites in Mouse: An Integrative Analysis.
- Author
-
Briard M, Guinot M, Grauso M, Guillon B, Hazebrouck S, Bernard H, Bouchaud G, Michel ML, and Adel-Patient K
- Subjects
- Allergens, Animals, Disease Models, Animal, Immunity, Innate, Lymphocytes, Mice, Mice, Inbred BALB C, Arachis, Food Hypersensitivity
- Abstract
Symptom occurrence at the first ingestion suggests that food allergy may result from earlier sensitization via non-oral routes. We aimed to characterize the cellular populations recruited at various mucosal and immune sites after experimental sensitization though different routes. BALB/cJ mice were exposed to a major allergenic food (peanut) mixed with cholera toxin via the intra-gastric (i.g.), respiratory, cutaneous, or intra-peritoneal (i.p.) route. We assessed sensitization and elicitation of the allergic reaction and frequencies of T cells, innate lymphoid cells (ILC), and inflammatory and dendritic cells (DC) in broncho-alveolar lavages (BAL), lungs, skin, intestine, and various lymph nodes. All cellular data were analyzed through non-supervised and supervised uni/multivariate analysis. All exposure routes, except cutaneous, induced sensitization, but intestinal allergy was induced only in i.g.- and i.p.-exposed mice. Multivariate analysis of all cellular constituents did not discriminate i.g. from control mice. Conversely, respiratory-sensitized mice constituted a distinct cluster, characterized by high local inflammation and immune cells recruitment. Those mice also evidenced changes in ILC frequencies at distant site (intestine). Despite absence of sensitization, cutaneous-exposed mice evidenced comparable changes, albeit less intense. Our study highlights that the initial route of sensitization to a food allergen influences the nature of the immune responses at various mucosal sites. Interconnections of mucosal immune systems may participate in the complexity of clinical manifestations as well as in the atopic march.
- Published
- 2022
- Full Text
- View/download PDF
22. Gut microbiota-derived short-chain fatty acids regulate IL-17 production by mouse and human intestinal γδ T cells.
- Author
-
Dupraz L, Magniez A, Rolhion N, Richard ML, Da Costa G, Touch S, Mayeur C, Planchais J, Agus A, Danne C, Michaudel C, Spatz M, Trottein F, Langella P, Sokol H, and Michel ML
- Subjects
- Adult, Animals, Cecum cytology, Female, Gastrointestinal Tract drug effects, Gastrointestinal Tract microbiology, Histone Deacetylase Inhibitors pharmacology, Humans, Inflammatory Bowel Diseases immunology, Inflammatory Bowel Diseases pathology, Interleukins biosynthesis, Male, Mice, Mice, Inbred C57BL, Middle Aged, Vancomycin pharmacology, Interleukin-22, Fatty Acids, Volatile pharmacology, Gastrointestinal Microbiome drug effects, Interleukin-17 biosynthesis, Intestines cytology, Receptors, Antigen, T-Cell, gamma-delta metabolism
- Abstract
Gut interleukin-17A (IL-17)-producing γδ T cells are tissue-resident cells that are involved in both host defense and regulation of intestinal inflammation. However, factors that regulate their functions are poorly understood. In this study, we find that the gut microbiota represses IL-17 production by cecal γδ T cells. Treatment with vancomycin, a Gram-positive bacterium-targeting antibiotic, leads to decreased production of short-chain fatty acids (SCFAs) by the gut microbiota. Our data reveal that these microbiota-derived metabolites, particularly propionate, reduce IL-17 and IL-22 production by intestinal γδ T cells. Propionate acts directly on γδ T cells to inhibit their production of IL-17 in a histone deacetylase-dependent manner. Moreover, the production of IL-17 by human IL-17-producing γδ T cells from patients with inflammatory bowel disease (IBD) is regulated by propionate. These data contribute to a better understanding of the mechanisms regulating gut γδ T cell functions and offer therapeutic perspectives of these cells., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
23. Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers.
- Author
-
Hehle V, Beretta M, Bourgine M, Ait-Goughoulte M, Planchais C, Morisse S, Vesin B, Lorin V, Hieu T, Stauffer A, Fiquet O, Dimitrov JD, Michel ML, Ungeheuer MN, Sureau C, Pol S, Di Santo JP, Strick-Marchand H, Pelletier N, and Mouquet H
- Subjects
- Animals, B-Lymphocytes immunology, Cross Reactions immunology, Enzyme-Linked Immunosorbent Assay, Epitopes immunology, Flow Cytometry, Hepatitis B immunology, Hepatitis B Surface Antigens immunology, Hepatitis B Vaccines immunology, Hepatitis B, Chronic immunology, Humans, Immunologic Memory immunology, Mice, Neutralization Tests, Antibodies, Neutralizing immunology, Hepatitis B virus immunology
- Abstract
Rare individuals can naturally clear chronic hepatitis B virus (HBV) infection and acquire protection from reinfection as conferred by vaccination. To examine the protective humoral response against HBV, we cloned and characterized human antibodies specific to the viral surface glycoproteins (HBsAg) from memory B cells of HBV vaccinees and controllers. We found that human HBV antibodies are encoded by a diverse set of immunoglobulin genes and recognize various conformational HBsAg epitopes. Strikingly, HBsAg-specific memory B cells from natural controllers mainly produced neutralizing antibodies able to cross-react with several viral genotypes. Furthermore, monotherapy with the potent broadly neutralizing antibody Bc1.187 suppressed viremia in vivo in HBV mouse models and led to post-therapy control of the infection in a fraction of animals. Thus, human neutralizing HBsAg antibodies appear to play a key role in the spontaneous control of HBV and represent promising immunotherapeutic tools for achieving HBV functional cure in chronically infected humans., Competing Interests: Disclosures: V. Hehle reported a patent to anti-HBV antibodies and methods of use, pending. M. Beretta reported a patent to anti-HBV antibodies and methods of use, pending. M. Bourgine reported a patent to anti-HBV antibodies and methods of use, pending. M. Ait-Goughoulte reported a patent planned on the antibodies pending, "Roche." S. Pol reported personal fees from Gilead, Abbvie, BMS, Janssen, and Roche outside the submitted work. H. Strick-Marchand reported a patent to human neutralizing HBV antibodies and their use thereof, pending. N. Pelletier reported personal fees from Hoffmann-La Roche outside the submitted work; in addition, N. Pelletier had a patent planned to be submitted, pending "Roche Innovation Center Basel." H. Mouquet reported grants from Institut Roche during the conduct of the study; in addition, H. Mouquet had a patent to anti-HBV antibodies and methods of use, pending. No other disclosures were reported., (© 2020 Hehle et al.)
- Published
- 2020
- Full Text
- View/download PDF
24. Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-Titer Hepatitis B Virus Carrier Mice.
- Author
-
Michler T, Kosinska AD, Festag J, Bunse T, Su J, Ringelhan M, Imhof H, Grimm D, Steiger K, Mogler C, Heikenwalder M, Michel ML, Guzman CA, Milstein S, Sepp-Lorenzino L, Knolle P, and Protzer U
- Subjects
- Animals, B-Lymphocytes immunology, Carrier State immunology, Carrier State virology, Combined Modality Therapy methods, Disease Models, Animal, Female, Gene Knockdown Techniques, Hepatitis B Surface Antigens immunology, Hepatitis B Vaccines administration & dosage, Hepatitis B virus genetics, Hepatitis B virus isolation & purification, Hepatitis B, Chronic diagnosis, Hepatitis B, Chronic immunology, Hepatitis B, Chronic virology, Hepatocytes virology, Humans, Immunization, Secondary, Immunogenicity, Vaccine, Male, Mice, T-Lymphocytes, Cytotoxic immunology, Virus Replication genetics, Virus Replication immunology, Hepatitis B Surface Antigens genetics, Hepatitis B Vaccines immunology, Hepatitis B virus immunology, Hepatitis B, Chronic therapy, RNA, Small Interfering administration & dosage
- Abstract
Background & Aims: Hepatitis B virus (HBV) infection persists because the virus-specific immune response is dysfunctional. Therapeutic vaccines might be used to end immune tolerance to the virus in patients with chronic infection, but these have not been effective in patients so far. In patients with chronic HBV infection, high levels of virus antigens might prevent induction of HBV-specific immune responses. We investigated whether knocking down expression levels of HBV antigens in liver might increase the efficacy of HBV vaccines in mice., Methods: We performed studies with male C57BL/6 mice that persistently replicate HBV (genotype D, serotype ayw)-either from a transgene or after infection with an adeno-associated virus that transferred an overlength HBV genome-and expressed HB surface antigen at levels relevant to patients. Small hairpin or small interfering (si)RNAs against the common 3'-end of all HBV transcripts were used to knock down antigen expression in mouse hepatocytes. siRNAs were chemically stabilized and conjugated to N-acetylgalactosamine to increase liver uptake. Control mice were given either entecavir or non-HBV-specific siRNAs and vaccine components. Eight to 12 weeks later, mice were immunized twice with a mixture of adjuvanted HBV S and core antigen, followed by a modified Vaccinia virus Ankara vector to induce HBV-specific B- and T-cell responses. Serum and liver samples were collected and analyzed for HBV-specific immune responses, liver damage, and viral parameters., Results: In both models of HBV infection, mice that express hepatocyte-specific small hairpin RNAs or that were given subcutaneous injections of siRNAs had reduced levels of HBV antigens, HBV replication, and viremia (1-3 log
10 reduction) compared to mice given control RNAs. Vaccination induced production of HBV-neutralizing antibodies and increased numbers and functionality of HBV-specific, CD8+ T cells in mice with low, but not in mice with high, levels of HBV antigen. Mice with initially high titers of HBV and knockdown of HBV antigen expression, but not mice with reduced viremia after administration of entecavir, developed polyfunctional, HBV-specific CD8+ T cells, and HBV was eliminated., Conclusions: In mice with high levels of HBV replication, knockdown of HBV antigen expression along with a therapeutic vaccination strategy, but not knockdown alone, increased numbers of effector T cells and eliminated the virus. These findings indicate that high titers of virus antigens reduce the efficacy of therapeutic vaccination. Anti-HBV siRNAs and therapeutic vaccines are each being tested in clinical trials-their combination might cure chronic HBV infection., (Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
25. Oral delivery of pancreatitis-associated protein by Lactococcus lactis displays protective effects in dinitro-benzenesulfonic-acid-induced colitis model and is able to modulate the composition of the microbiota.
- Author
-
Breyner NM, Vilas Boas PB, Fernandes G, de Carvalho RD, Rochat T, Michel ML, Chain F, Sokol H, de Azevedo M, Myioshi A, Azevedo VA, Langella P, Bermúdez-Humarán LG, and Chatel JM
- Subjects
- Animals, Antimicrobial Cationic Peptides metabolism, Benzenesulfonates toxicity, Colitis chemically induced, Colitis pathology, Colon metabolism, Dextran Sulfate toxicity, Disease Models, Animal, Inflammation, Mice, Mice, Inbred C57BL, Pancreatitis-Associated Proteins metabolism, Peptides metabolism, Antimicrobial Cationic Peptides therapeutic use, Colitis drug therapy, Gastrointestinal Microbiome drug effects, Lactococcus lactis metabolism, Pancreatitis-Associated Proteins therapeutic use
- Abstract
Antimicrobial peptides secreted by intestinal immune and epithelial cells are important effectors of innate immunity. They play an essential role in the maintenance of intestinal homeostasis by limiting microbial epithelium interactions and preventing unnecessary microbe-driven inflammation. Pancreatitis-associated protein (PAP) belongs to Regenerating islet-derived III proteins family and is a C-type (Ca
+2 dependent) lectin. PAP protein plays a protective effect presenting anti-inflammatory properties able to reduce the severity of colitis, preserving gut barrier and epithelial inflammation. Here, we sought to determine whether PAP delivered at intestinal lumen by recombinant Lactococcus lactis strain (LL-PAP) before and after chemically induced colitis is able to reduce the severity in two models of colitis. After construction and characterization of our recombinant strains, we tested their effects in dinitro-benzenesulfonic-acid (DNBS) and Dextran sulfate sodium (DSS) colitis model. After the DNBS challenge, mice treated with LL-PAP presented less severe colitis compared with PBS and LL-empty-treated mice groups. After the DSS challenge, no protective effects of LL-PAP could be detected. We determined that after 5 days administration, LL-PAP increase butyrate producer's bacteria, especially Eubacterium plexicaudatum. Based on our findings, we hypothesize that a treatment with LL-PAP shifts the microbiota preventing the severity of colon inflammation in DNBS colitis model. These protective roles of LL-PAP in DNBS colitis model might be through intestinal microbiota modulation., (© 2019 The Authors. Environmental Microbiology published by Society for Applied Microbiology and John Wiley & Sons Ltd.)- Published
- 2019
- Full Text
- View/download PDF
26. Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection.
- Author
-
Kosinska AD, Moeed A, Kallin N, Festag J, Su J, Steiger K, Michel ML, Protzer U, and Knolle PA
- Subjects
- Adjuvants, Immunologic administration & dosage, Animals, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, Cells, Cultured, Female, Hepatitis B Core Antigens immunology, Hepatitis B Vaccines therapeutic use, Hepatitis B, Chronic immunology, Liver immunology, Male, Mice, Oligodeoxyribonucleotides administration & dosage, Vaccines, DNA, Viral Vaccines immunology, Adjuvants, Immunologic therapeutic use, Hepatitis B Vaccines immunology, Hepatitis B, Chronic prevention & control, Oligodeoxyribonucleotides therapeutic use, Vaccination methods
- Abstract
Therapeutic vaccination against chronic hepatitis B must overcome high viral antigen load and local regulatory mechanisms that promote immune-tolerance in the liver and curtail hepatitis B virus (HBV)-specific CD8 T cell immunity. Here, we report that therapeutic heterologous HBcore-protein-prime/Modified-Vaccinia-Virus-Ankara (MVA-HBcore) boost vaccination followed by CpG-application augmented vaccine-induced HBcAg-specific CD8 T cell-function in the liver. In HBV-transgenic as well as AAV-HBV-transduced mice with persistent high-level HBV-replication, the combination of therapeutic vaccination with subsequent CpG-application was synergistic to generate more potent HBV-specific CD8 T cell immunity that improved control of hepatocytes replicating HBV.
- Published
- 2019
- Full Text
- View/download PDF
27. Elucidating the Immune-Related Mechanisms by Which Probiotic Strain Lactobacillus casei BL23 Displays Anti-tumoral Properties.
- Author
-
Jacouton E, Michel ML, Torres-Maravilla E, Chain F, Langella P, and Bermúdez-Humarán LG
- Abstract
We have recently described antitumor properties of Lactobacillus casei BL23 strain in both a mouse allograft model of human papilloma virus (HPV)-induced cancer and dimethylhydrazine-associated colorectal cancer. However, the mechanisms underlying these beneficial effects are still unknown. Interestingly, in vitro cellular models show that this bacterium is able to stimulate the production of high levels of IL-2. Because this cytokine has well-known antitumor properties, we decided to explore its role in the anti-cancer effects of BL23 using the HPV-induced cancer model. We found a negative correlation between IL-2 and tumor size confirming the necessity of IL-2 to protect from tumor development. Then, we blocked IL-2 synthesis using neutralizing monoclonal antibodies in mice that were challenged with lethal levels of tumor cells; this led to a significant reduction in the protective abilities of BL23. Next, we used a genetically modified strain of Lactococcus lactis to deliver exogenous IL-2 to the system, and in doing so, we were able to partially mimic the antitumor properties of BL23. Additionally, we showed the systemic role of T-cells in tumor protection through a negative correlation between tumor size and T-cells subpopulations and an increasement of BL23-specific local Foxp3 levels in tumor-bearing mice. Finally, we observed a negative correlation between tumor size and NK+ cells, but local recruitment of NK cells and cytotoxic activity appeared specific to BL23 treatment. Taken together, our data suggest that IL-2 signaling pathway plays an important role in the anti-tumoral effects of probiotic strain L. casei BL23. These results encourage further investigation in the use of probiotic strains for potential therapeutic applications to clinical practice, in particular for the treatment of colorectal cancer. Furthermore, our approach could be extended and applied to other potential beneficial microorganisms, such as gut microbiota, in order to better understand the crosstalk between microbes and the host.
- Published
- 2019
- Full Text
- View/download PDF
28. Impaired Aryl Hydrocarbon Receptor Ligand Production by the Gut Microbiota Is a Key Factor in Metabolic Syndrome.
- Author
-
Natividad JM, Agus A, Planchais J, Lamas B, Jarry AC, Martin R, Michel ML, Chong-Nguyen C, Roussel R, Straube M, Jegou S, McQuitty C, Le Gall M, da Costa G, Lecornet E, Michaudel C, Modoux M, Glodt J, Bridonneau C, Sovran B, Dupraz L, Bado A, Richard ML, Langella P, Hansel B, Launay JM, Xavier RJ, Duboc H, and Sokol H
- Subjects
- Animals, Limosilactobacillus reuteri metabolism, Ligands, Male, Metabolic Syndrome drug therapy, Metabolic Syndrome therapy, Mice, Mice, Inbred C57BL, Probiotics therapeutic use, Receptors, Aryl Hydrocarbon agonists, Gastrointestinal Microbiome, Metabolic Syndrome metabolism, Metabolic Syndrome microbiology, Receptors, Aryl Hydrocarbon metabolism, Tryptophan metabolism
- Abstract
The extent to which microbiota alterations define or influence the outcome of metabolic diseases is still unclear, but the byproducts of microbiota metabolism are known to have an important role in mediating the host-microbiota interaction. Here, we identify that in both pre-clinical and clinical settings, metabolic syndrome is associated with the reduced capacity of the microbiota to metabolize tryptophan into derivatives that are able to activate the aryl hydrocarbon receptor. This alteration is not merely an effect of the disease as supplementation with AhR agonist or a Lactobacillus strain, with a high AhR ligand-production capacity, leads to improvement of both dietary- and genetic-induced metabolic impairments, particularly glucose dysmetabolism and liver steatosis, through improvement of intestinal barrier function and secretion of the incretin hormone GLP-1. These results highlight the role of gut microbiota-derived metabolites as a biomarker and as a basis for novel preventative or therapeutic interventions for metabolic disorders., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
29. Card9 mediates susceptibility to intestinal pathogens through microbiota modulation and control of bacterial virulence.
- Author
-
Lamas B, Michel ML, Waldschmitt N, Pham HP, Zacharioudaki V, Dupraz L, Delacre M, Natividad JM, Costa GD, Planchais J, Sovran B, Bridonneau C, Six A, Langella P, Richard ML, Chamaillard M, and Sokol H
- Subjects
- Adaptive Immunity physiology, Animals, Citrobacter rodentium drug effects, Citrobacter rodentium pathogenicity, Diet Therapy methods, Gene-Environment Interaction, Genetic Predisposition to Disease, Host-Pathogen Interactions immunology, Immunity, Innate physiology, Mice, Virulence physiology, CARD Signaling Adaptor Proteins genetics, CARD Signaling Adaptor Proteins metabolism, Colitis immunology, Colitis microbiology, Gastrointestinal Microbiome physiology, Polysaccharides adverse effects, Polysaccharides metabolism
- Abstract
Objective: In association with innate and adaptive immunity, the microbiota controls the colonisation resistance against intestinal pathogens. Caspase recruitment domain 9 ( CARD9 ), a key innate immunity gene, is required to shape a normal gut microbiota. Card9
-/- mice are more susceptible to the enteric mouse pathogen Citrobacter rodentium that mimics human infections with enteropathogenic and enterohaemorrhagic Escherichia coli . Here, we examined how CARD9 controls C. rodentium infection susceptibility through microbiota-dependent and microbiota-independent mechanisms., Design: C. rodentium infection was assessed in conventional and germ-free (GF) wild-type (WT) and Card9-/- mice. To explore the impact of Card9-/- microbiota in infection susceptibility, GF WT mice were colonised with WT (WT→GF) or Card9-/- ( Card9-/- →GF) microbiota before C. rodentium infection. Microbiota composition was determined by 16S rDNA gene sequencing. Inflammation severity was determined by histology score and lipocalin level. Microbiota-host immune system interactions were assessed by quantitative PCR analysis., Results: CARD9 controls pathogen virulence in a microbiota-independent manner by supporting a specific humoral response. Higher susceptibility to C. rodentium -induced colitis was observed in Card9-/- →GF mice. The microbiota of Card9-/- mice failed to outcompete the monosaccharide-consuming C. rodentium , worsening the infection severity. A polysaccharide-enriched diet counteracted the ecological advantage of C. rodentium and the defective pathogen-specific antibody response in Card9-/- mice., Conclusions: CARD9 modulates the susceptibility to intestinal infection by controlling the pathogen virulence in a microbiota-dependent and microbiota-independent manner. Genetic susceptibility to intestinal pathogens can be overridden by diet intervention that restores humoural immunity and a competing microbiota., Competing Interests: Competing interests: None declared., (© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.)- Published
- 2018
- Full Text
- View/download PDF
30. Enterobacteriaceae are essential for the modulation of colitis severity by fungi.
- Author
-
Sovran B, Planchais J, Jegou S, Straube M, Lamas B, Natividad JM, Agus A, Dupraz L, Glodt J, Da Costa G, Michel ML, Langella P, Richard ML, and Sokol H
- Subjects
- Animals, Antibiosis, Antibodies administration & dosage, Candida albicans genetics, Candida albicans isolation & purification, Colitis drug therapy, Disease Models, Animal, Enterobacteriaceae classification, Enterobacteriaceae genetics, Enterobacteriaceae isolation & purification, Female, Gastrointestinal Microbiome, Humans, Mice, Mice, Inbred C57BL, Saccharomyces boulardii genetics, Saccharomyces boulardii isolation & purification, Candida albicans physiology, Colitis microbiology, Enterobacteriaceae physiology, Saccharomyces boulardii physiology
- Abstract
Background: Host-microbe balance maintains intestinal homeostasis and strongly influences inflammatory conditions such as inflammatory bowel diseases (IBD). Here we focused on bacteria-fungi interactions and their implications on intestinal inflammation, a poorly understood area., Methods: Dextran sodium sulfate (DSS)-induced colitis was assessed in mice treated with vancomycin (targeting gram-positive bacteria) or colistin (targeting Enterobacteriaceae) and supplemented with either Saccharomyces boulardii CNCM I-745 or Candida albicans. Inflammation severity as well as bacterial and fungal microbiota compositions was monitored., Results: While S. boulardii improved DSS-induced colitis and C. albicans worsened it in untreated settings, antibiotic treatment strongly modified DSS susceptibility and effects of fungi on colitis. Vancomycin-treated mice were fully protected from colitis, while colistin-treated mice retained colitis phenotype but were not affected anymore by administration of fungi. Antibacterial treatments not only influenced bacterial populations but also had indirect effects on fungal microbiota. Correlations between bacterial and fungal relative abundance were dramatically decreased in colistin-treated mice compared to vancomycin-treated and control mice, suggesting that colistin-sensitive bacteria are involved in interactions with fungi. Restoration of the Enterobacteriaceae population by administrating colistin-resistant Escherichia coli reestablished both beneficial effects of S. boulardii and pathogenic effects of C. albicans on colitis severity. This effect was at least partly mediated by an improved gut colonization by fungi., Conclusions: Fungal colonization of the gut is affected by the Enterobacteriaceae population, indirectly modifying effects of mycobiome on the host. This finding provides new insights into the role of inter-kingdom functional interactions in intestinal physiopathology and potentially in IBD.
- Published
- 2018
- Full Text
- View/download PDF
31. Bilophila wadsworthia aggravates high fat diet induced metabolic dysfunctions in mice.
- Author
-
Natividad JM, Lamas B, Pham HP, Michel ML, Rainteau D, Bridonneau C, da Costa G, van Hylckama Vlieg J, Sovran B, Chamignon C, Planchais J, Richard ML, Langella P, Veiga P, and Sokol H
- Subjects
- Animals, Bilophila growth & development, Blood Glucose metabolism, Cytokines biosynthesis, Cytokines genetics, Desulfovibrionaceae Infections etiology, Desulfovibrionaceae Infections metabolism, Desulfovibrionaceae Infections therapy, Diet, High-Fat adverse effects, Fatty Liver etiology, Fatty Liver metabolism, Fatty Liver therapy, Gastrointestinal Microbiome, Liver microbiology, Liver pathology, Liver Function Tests, Male, Metabolic Networks and Pathways genetics, Metabolic Syndrome etiology, Metabolic Syndrome metabolism, Metabolic Syndrome therapy, Mice, Mice, Inbred C57BL, Transcriptome, Bilophila pathogenicity, Desulfovibrionaceae Infections microbiology, Dietary Fats adverse effects, Fatty Liver microbiology, Lacticaseibacillus rhamnosus physiology, Metabolic Syndrome microbiology, Probiotics pharmacology
- Abstract
Dietary lipids favor the growth of the pathobiont Bilophila wadsworthia, but the relevance of this expansion in metabolic syndrome pathogenesis is poorly understood. Here, we showed that B. wadsworthia synergizes with high fat diet (HFD) to promote higher inflammation, intestinal barrier dysfunction and bile acid dysmetabolism, leading to higher glucose dysmetabolism and hepatic steatosis. Host-microbiota transcriptomics analysis reveal pathways, particularly butanoate metabolism, which may underlie the metabolic effects mediated by B. wadsworthia. Pharmacological suppression of B. wadsworthia-associated inflammation demonstrate the bacterium's intrinsic capacity to induce a negative impact on glycemic control and hepatic function. Administration of the probiotic Lactobacillus rhamnosus CNCM I-3690 limits B. wadsworthia-induced immune and metabolic impairment by limiting its expansion, reducing inflammation and reinforcing intestinal barrier. Our results suggest a new avenue for interventions against western diet-driven inflammatory and metabolic diseases.
- Published
- 2018
- Full Text
- View/download PDF
32. Nasal route favors the induction of CD4 + T cell responses in the liver of HBV-carrier mice immunized with a recombinant hepatitis B surface- and core-based therapeutic vaccine.
- Author
-
Bourgine M, Crabe S, Lobaina Y, Guillen G, Aguilar JC, and Michel ML
- Subjects
- Administration, Intranasal, Animals, Disease Models, Animal, Hepatitis B Antibodies blood, Hepatitis B Core Antigens immunology, Hepatitis B Surface Antigens immunology, Hepatitis B Vaccines administration & dosage, Injections, Subcutaneous, Mice, Spleen immunology, Treatment Outcome, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic immunology, CD4-Positive T-Lymphocytes immunology, Carrier State therapy, Hepatitis B therapy, Hepatitis B Vaccines immunology, Hepatitis B virus immunology, Liver pathology
- Abstract
Immunization routes and number of doses remain largely unexplored in therapeutic vaccination. The aim of the present work is to evaluate their impact on immune responses in naïve and hepatitis B virus (HBV)-carrier mouse models following immunization with a non-adjuvanted recombinant vaccine comprising the hepatitis B surface (HBsAg) and core (HBcAg) antigens. Mice were immunized either by intranasal (i.n.), subcutaneous (s.c.) or simultaneous (i.n. + s.c.) routes. Humoral immunity was detected in all the animal models with the induction of a potent antibody (Ab) response against HBcAg, which was stronger than the anti-HBs response. In the HBV-carrier mouse model, the anti-HBs response was predominantly subtype-specific and preferentially induced by the i.n. route. However, the Ab titers were not sufficient to clear the high concentration of HBsAg present in the sera of these mice. The i.n. route was the most efficacious at inducing cellular immune responses, in particular CD4
+ T cells. In naïve mice, cellular responses in spleen were strong and mainly due to CD4+ T cells whereas the CD8+ T-cell response was low. In HBV-carrier mice, high frequencies of HBs-specific CD4+ T cells secreting interferon (IFN)-γ, interleukin (IL)-2 and tumor necrosis factor (TNF)-α were found in liver only after i.n. immunization. Increased frequencies of CD4+ T cells expressing the integrin CD49a in liver suggest a role of nasal route in the cellular homing process. Multiple dose schedules appear to be a prerequisite for protein-based immunization in order to overcome immunotolerance in HBV-carrier mice. These findings provide new avenues for further preclinical and clinical development., (Copyright © 2018 Elsevier B.V. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
33. Detection of the hepatitis B virus (HBV) covalently-closed-circular DNA (cccDNA) in mice transduced with a recombinant AAV-HBV vector.
- Author
-
Lucifora J, Salvetti A, Marniquet X, Mailly L, Testoni B, Fusil F, Inchauspé A, Michelet M, Michel ML, Levrero M, Cortez P, Baumert TF, Cosset FL, Challier C, Zoulim F, and Durantel D
- Subjects
- Animals, Blotting, Southern, DNA Replication, Disease Models, Animal, Hepatitis B drug therapy, Hepatocytes virology, Liver virology, Mice, Plasmids, Polymerase Chain Reaction methods, Transduction, Genetic, DNA, Circular isolation & purification, DNA, Viral isolation & purification, Dependovirus genetics, Genetic Vectors, Hepatitis B virology, Hepatitis B virus genetics
- Abstract
Hepatitis B Virus (HBV) persists in infected hepatocytes as an episomal covalently-closed-circular DNA mini-chromosome, called cccDNA. As the main nuclear transcription template, HBV cccDNA is a key replication intermediate in the viral life cycle. Little is known about the mechanisms involved in its formation, maintenance and fate under antiviral therapies. This is mainly due to the lack of small immune-competent animal models able to recapitulate the entire HBV replication cycle, including formation of HBV cccDNA. Here we report that HBV cccDNA can be detected by Southern blot analyses in the liver of C57BL6 mice transduced with AAV-HBV. HBV cccDNA persists in the liver of these animals together with the AAV-HBV episome. We also set up a PCR strategy to distinguish the HBV cccDNA from the AAV-HBV episome. These suggest that the AAV-HBV/mouse model might be relevant to test drugs targeting HBV cccDNA regulation and persistence., (Copyright © 2017. Published by Elsevier B.V.)
- Published
- 2017
- Full Text
- View/download PDF
34. Chronic hepatitis B: Immunological profile and current therapeutic vaccines in clinical trials.
- Author
-
Lobaina Y and Michel ML
- Subjects
- Antiviral Agents administration & dosage, Combined Modality Therapy methods, Drug Therapy methods, Humans, Hepatitis B Vaccines administration & dosage, Hepatitis B virus immunology, Hepatitis B, Chronic immunology, Hepatitis B, Chronic therapy, Immunotherapy methods
- Abstract
More than 250million people worldwide are chronically infected with hepatitis B virus (CHB), and over half a million die each year due to CHB-associated liver complications such as cirrhosis and hepatocellular carcinoma. The translation of immunological knowledge about CHB into therapeutic strategies aiming to a sustainable hepatitis B virus (HBV) clearance has been challenging. In recent years, however, the understanding on the immune effectors required to overcome chronicity has notably increased thanks to preclinical and clinical research. Therapeutic vaccination may prove to be useful for treating CHB patients when coupled with current antiviral agents and other immunomodulatory strategies. This review summarizes current data and future perspectives on therapeutic vaccination. Other treatment alternatives that could be combined with vaccines for a complete cure from hepatitis B virus infection are also discussed., (Copyright © 2017 Elsevier Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
35. Single-Nucleotide Resolution Mapping of Hepatitis B Virus Promoters in Infected Human Livers and Hepatocellular Carcinoma.
- Author
-
Altinel K, Hashimoto K, Wei Y, Neuveut C, Gupta I, Suzuki AM, Dos Santos A, Moreau P, Xia T, Kojima S, Kato S, Takikawa Y, Hidaka I, Shimizu M, Matsuura T, Tsubota A, Ikeda H, Nagoshi S, Suzuki H, Michel ML, Samuel D, Buendia MA, Faivre J, and Carninci P
- Subjects
- Adult, Aged, Animals, Chromosome Mapping, Female, Genome, Viral, Hep G2 Cells, Hepatitis B virus pathogenicity, Humans, Liver virology, Male, Mice, Middle Aged, RNA Caps genetics, RNA, Viral genetics, Transcription Initiation Site, Transcriptome, Carcinoma, Hepatocellular virology, Hepatitis B virus genetics, Hepatitis B, Chronic virology, Liver Neoplasms virology, Promoter Regions, Genetic
- Abstract
Hepatitis B virus (HBV) is a major cause of liver diseases, including hepatocellular carcinoma (HCC), and more than 650,000 people die annually due to HBV-associated liver failure. Extensive studies of individual promoters have revealed that heterogeneous RNA 5' ends contribute to the complexity of HBV transcriptome and proteome. Here, we provide a comprehensive map of HBV transcription start sites (TSSs) in human liver, HCC, and blood, as well as several experimental replication systems, at a single-nucleotide resolution. Using CAGE (cap analysis of gene expression) analysis of 16 HCC/nontumor liver pairs, we identify 17 robust TSSs, including a novel promoter for the X gene located in the middle of the gene body, which potentially produces a shorter X protein translated from the conserved second start codon, and two minor antisense transcripts that might represent viral noncoding RNAs. Interestingly, transcription profiles were similar in HCC and nontumor livers, although quantitative analysis revealed highly variable patterns of TSS usage among clinical samples, reflecting precise regulation of HBV transcription initiation at each promoter. Unlike the variety of TSSs found in liver and HCC, the vast majority of transcripts detected in HBV-positive blood samples are pregenomic RNA, most likely generated and released from liver. Our quantitative TSS mapping using the CAGE technology will allow better understanding of HBV transcriptional responses in further studies aimed at eradicating HBV in chronic carriers., Importance: Despite the availability of a safe and effective vaccine, HBV infection remains a global health problem, and current antiviral protocols are not able to eliminate the virus in chronic carriers. Previous studies of the regulation of HBV transcription have described four major promoters and two enhancers, but little is known about their activity in human livers and HCC. We deeply sequenced the HBV RNA 5' ends in clinical human samples and experimental models by using a new, sensitive and quantitative method termed cap analysis of gene expression (CAGE). Our data provide the first comprehensive map of global TSS distribution over the entire HBV genome in the human liver, validating already known promoters and identifying novel locations. Better knowledge of HBV transcriptional activity in the clinical setting has critical implications in the evaluation of therapeutic approaches that target HBV replication., (Copyright © 2016 Altinel et al.)
- Published
- 2016
- Full Text
- View/download PDF
36. SLAM-associated protein favors the development of iNKT2 over iNKT17 cells.
- Author
-
Michel ML, Lenoir C, Massot B, Diem S, Pasquier B, Sawa S, Rignault-Bricard R, Lehuen A, Eberl G, Veillette A, Leite-de-Moraes M, and Latour S
- Subjects
- Animals, Biomarkers, Cells, Cultured, Immunophenotyping, Interleukin-17 biosynthesis, Interleukin-4 biosynthesis, Mice, Mice, Knockout, Mice, Transgenic, Nuclear Receptor Subfamily 1, Group F, Member 3 metabolism, Phenotype, Signaling Lymphocytic Activation Molecule Associated Protein deficiency, Signaling Lymphocytic Activation Molecule Associated Protein genetics, Cell Differentiation immunology, Natural Killer T-Cells cytology, Natural Killer T-Cells metabolism, Signaling Lymphocytic Activation Molecule Associated Protein metabolism, T-Lymphocyte Subsets cytology, T-Lymphocyte Subsets metabolism
- Abstract
Invariant NKT (iNKT) cells differentiate in the thymus into three distinct lineages defined by their cytokine and transcription factor expression. Signaling lymphocyte activation molecule (SLAM)-associated protein (SAP) is essential for early stages of iNKT cell development, but its role during terminal differentiation of iNKT1, iNKT2, or iNKT17 cells remains unclear. Taking advantage of SAP-deficient mice expressing a Vα14-Jα18 TCRα transgene, we found that SAP is critical not only for IL-4 production but also for the terminal differentiation of IL-4-producing iNKT2 cells. Furthermore, without SAP, the IL-17 producing subset is expanded, while IFN-γ-producing iNKT1 differentiation is only moderately compromised. Lack of SAP reduced the expression of the transcription factors GATA-3 and promyelocytic leukemia zinc finger, but enhanced the levels of retinoic acid receptor-related orphan receptor γt. In the absence of SAP, lineage commitment was actually shifted toward the emergence of iNKT17 over iNKT2 cells. Collectively, our data unveil a new critical regulatory function for SAP in thymic iNKT cell fate decisions., (© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)
- Published
- 2016
- Full Text
- View/download PDF
37. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands.
- Author
-
Lamas B, Richard ML, Leducq V, Pham HP, Michel ML, Da Costa G, Bridonneau C, Jegou S, Hoffmann TW, Natividad JM, Brot L, Taleb S, Couturier-Maillard A, Nion-Larmurier I, Merabtene F, Seksik P, Bourrier A, Cosnes J, Ryffel B, Beaugerie L, Launay JM, Langella P, Xavier RJ, and Sokol H
- Subjects
- Adolescent, Adult, Animals, CARD Signaling Adaptor Proteins genetics, Chromatography, High Pressure Liquid, Colitis chemically induced, Colitis pathology, Colon immunology, Colon microbiology, Colon pathology, Cytokines immunology, Dextran Sulfate toxicity, Fecal Microbiota Transplantation, Female, Gastrointestinal Microbiome genetics, Gene Expression Profiling, Humans, Inflammatory Bowel Diseases genetics, Inflammatory Bowel Diseases immunology, Male, Mice, Mice, Knockout, Middle Aged, RNA, Ribosomal, 16S genetics, Reverse Transcriptase Polymerase Chain Reaction, Tryptophan immunology, Young Adult, Interleukin-22, CARD Signaling Adaptor Proteins immunology, Colitis immunology, Gastrointestinal Microbiome immunology, Interleukins immunology, Lactobacillus metabolism, Receptors, Aryl Hydrocarbon immunology, Tryptophan metabolism
- Abstract
Complex interactions between the host and the gut microbiota govern intestinal homeostasis but remain poorly understood. Here we reveal a relationship between gut microbiota and caspase recruitment domain family member 9 (CARD9), a susceptibility gene for inflammatory bowel disease (IBD) that functions in the immune response against microorganisms. CARD9 promotes recovery from colitis by promoting interleukin (IL)-22 production, and Card9(-/-) mice are more susceptible to colitis. The microbiota is altered in Card9(-/-) mice, and transfer of the microbiota from Card9(-/-) to wild-type, germ-free recipients increases their susceptibility to colitis. The microbiota from Card9(-/-) mice fails to metabolize tryptophan into metabolites that act as aryl hydrocarbon receptor (AHR) ligands. Intestinal inflammation is attenuated after inoculation of mice with three Lactobacillus strains capable of metabolizing tryptophan or by treatment with an AHR agonist. Reduced production of AHR ligands is also observed in the microbiota from individuals with IBD, particularly in those with CARD9 risk alleles associated with IBD. Our findings reveal that host genes affect the composition and function of the gut microbiota, altering the production of microbial metabolites and intestinal inflammation., Competing Interests: The authors declare no competing financial interests.
- Published
- 2016
- Full Text
- View/download PDF
38. Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study.
- Author
-
Piroth L, Launay O, Michel ML, Bourredjem A, Miailhes P, Ajana F, Chirouze C, Zucman D, Wendling MJ, Nazzal D, Carrat F, Rey D, and Binquet C
- Subjects
- Adult, Antiretroviral Therapy, Highly Active, Female, HIV Infections drug therapy, HIV Infections immunology, Hepatitis B Antibodies immunology, Hepatitis B Vaccines immunology, Humans, Immunogenicity, Vaccine, Male, Middle Aged, Prospective Studies, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic immunology, HIV Infections complications, HIV-1, Hepatitis B prevention & control, Hepatitis B Antibodies isolation & purification, Hepatitis B Core Antigens immunology, Hepatitis B Vaccines administration & dosage
- Abstract
Background: Although an isolated anti-hepatitis B virus (HBV) core antibody (anti-HBc) serological profile is frequent in human immunodeficiency virus (HIV)-infected patients, data on HBV vaccination in these patients are scarce., Methods: A prospective multicenter study was conducted to assess the immunogenicity of HBV vaccination in 54 patients with an isolated anti-HBc profile and undetectable HIV load. They were vaccinated with 1 dose (20 µg) of recombinant HBV vaccine. Those with an anti-HBV surface antibody (anti-HBs) level of <10 mIU/mL 4 weeks after vaccination received 3 additional double doses (40 µg) at weeks 5, 9, and 24., Results: At week 4, 25 patients (46%) were responders. Only the ratio of CD4(+) T cells to CD8(+) T cells was associated with this response in multivariate analysis (odds ratio for +0.1, 1.32; 95% confidence interval, 1.07-1.63; P = .008). At week 28 and month 18, 58% of these patients (14 of 24) and 50% (10 of 20), respectively, maintained anti-HBs level of ≥10 mIU/mL.Among nonresponding patients at week 4, who received further vaccinations, 89% (24 of 27) and 81% (21 of 26) had an anti-HBs level of ≥10 mIU/mL at week 28 and month 18, respectively. The preS2-specific interferon γ T-cell response increased between week 0 and week 28 in patients who finally responded to reinforced vaccination (P = .03)., Conclusions: All of the patients with an isolated anti-HBc profile who did not have an anti-HBs titer of >100 mIU/mL 4 weeks after a single recall dose of HBV vaccine should be further vaccinated with a reinforced triple double-dose scheme., (© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.)
- Published
- 2016
- Full Text
- View/download PDF
39. Long-term Immune Response to Hepatitis B Virus Vaccination Regimens in Adults With Human Immunodeficiency Virus 1: Secondary Analysis of a Randomized Clinical Trial.
- Author
-
Launay O, Rosenberg AR, Rey D, Pouget N, Michel ML, Reynes J, Neau D, Raffi F, Piroth L, and Carrat F
- Subjects
- Adult, Biomarkers blood, Female, Follow-Up Studies, France, Humans, Injections, Intradermal methods, Injections, Intramuscular methods, Male, Middle Aged, Single-Blind Method, Treatment Outcome, Vaccination methods, HIV Infections immunology, HIV-1, Hepatitis B immunology, Hepatitis B prevention & control, Hepatitis B Antibodies blood, Hepatitis B Vaccines administration & dosage, Hepatitis B Vaccines immunology
- Abstract
Importance: Data on long-term immune responses to hepatitis B virus (HBV) vaccination in adults with human immunodeficiency virus 1 (HIV-1) infection are scarce., Objective: To compare long-term (up to month 42) immune responses to the standard HBV vaccination regimen with a 4-injection intramuscular double-dose regimen and a 4-injection intradermal low-dose regimen., Design, Setting, and Participants: The phase 3, open-label, multicenter parallel-group (1:1:1 allocation ratio) randomized clinical trial was conducted from June 28, 2007, to October 23, 2008, at 33 centers in France. Participants included 437 HBV-seronegative adults with HIV-1 and CD4 cell counts of more than 200/μL. Follow-up was extended to September 12, 2012, and data were assessed from February 13, 2015, to January 22, 2016. The analysis was imputed for an intention-to-treat population., Interventions: Patients were randomly assigned to receive 3 intramuscular standard-dose (20-μg) injections of recombinant HBV vaccine at weeks 0, 4, and 24 (IM20 × 3 group) (145 participants), 4 intramuscular double-dose (40-μg) injections at weeks 0, 4, 8, and 24 (IM40 × 4 group) (148 participants), or 4 intradermal low-dose (4-μg) injections at weeks 0, 4, 8, and 24 (ID4 × 4 group) (144 participants)., Main Outcomes and Measures: The previously published primary trial end point was the percentage of responders at week 28, defined as patients with hepatitis B surface antibody (HBsAb) levels of at least 10 mIU/mL among patients who received at least 1 vaccine dose. The secondary trial end points included the percentage of responders at months 18, 30, and 42 and the duration of response from week 28. Multiple imputation was used to address missing measurements during the follow-up., Results: Among the 437 patients randomized, 426 received at least 1 dose of vaccine. Of these, 287 were men (67.4%) and they had a mean (SD) age of 42.9 (9.7) years. The percentage of responders at month 42 was 41% (95% CI, 33%-49%) in the IM20 × 3 group, 71% (95% CI, 64%-79%) in the IM40 × 4 group (P < .001 vs the IM20 × 3 group), and 44% (95% CI, 35%-53%) in the ID4 × 4 group (P = .64 vs IM20 × 3 group). Fifteen percent of the patients had HBsAb titers of less than 10 mIU/mL at 33.1 months in the IM40 × 4 group, 8.7 months in the IM20 × 3 group, and 6.8 months in the ID4 × 4 group., Conclusions and Relevance: In this follow-up of a trial of adults with HIV-1 infection, the IM40 × 4 regimen of recombinant HBV vaccine improved long-term immune response compared with the standard regimen., Trial Registration: clinicaltrials.gov Identifier: NCT00480792.
- Published
- 2016
- Full Text
- View/download PDF
40. [Vaccination against hepatitis B: success and challenges].
- Author
-
Michel ML
- Subjects
- Carcinoma, Hepatocellular epidemiology, Carcinoma, Hepatocellular virology, Hepatitis B epidemiology, Hepatitis B transmission, Hepatitis B virus pathogenicity, Humans, Liver Neoplasms epidemiology, Liver Neoplasms virology, Hepatitis B prevention & control, Hepatitis B Vaccines therapeutic use, Vaccination methods, Vaccination standards, Vaccination statistics & numerical data
- Abstract
Hepatitis B virus is a worldwide leading cause of acute and chronic liver disease including cirrhosis and hepatocellular carcinoma. Effective vaccines have been available since the early '80s. Vaccination against hepatitis B virus infection has proved highly successful in reducing the disease burden, the development of the carrier state and the hepatitis B-related morbidity and mortality in the countries where vaccination has been implemented. Despite success and efficacy of preventive vaccines, a huge number of chronically infected patients still remain. Therapeutic vaccination may prove to be useful coupled with current antivirals and other immunomodulatory approaches to treat these patients. This review summarizes current unresolved issues and future perspectives on vaccination required for global cure of hepatitis B virus infection., (© 2016 médecine/sciences – Inserm.)
- Published
- 2016
- Full Text
- View/download PDF
41. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.
- Author
-
Martin P, Dubois C, Jacquier E, Dion S, Mancini-Bourgine M, Godon O, Kratzer R, Lelu-Santolaria K, Evlachev A, Meritet JF, Schlesinger Y, Villeval D, Strub JM, Van Dorsselaer A, Marchand JB, Geist M, Brandely R, Findeli A, Boukhebza H, Menguy T, Silvestre N, Michel ML, and Inchauspé G
- Subjects
- Adenoviridae classification, Alanine Transaminase blood, Animals, DNA-Directed DNA Polymerase genetics, DNA-Directed DNA Polymerase immunology, Disease Models, Animal, Gene Products, env genetics, Gene Products, env immunology, Genetic Vectors, HLA-A2 Antigen genetics, Hepatitis B Core Antigens genetics, Hepatitis B Core Antigens immunology, Hepatitis B Surface Antigens blood, Hepatitis B, Chronic blood, Interferon-gamma blood, Lymphocyte Count, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Transgenic, Time Factors, Tumor Necrosis Factor-alpha blood, Viral Fusion Proteins genetics, Viral Load, Adenoviridae metabolism, CD8-Positive T-Lymphocytes metabolism, DNA, Viral blood, Hepatitis B virus immunology, Hepatitis B, Chronic therapy, Immunotherapy methods, Viral Fusion Proteins immunology
- Abstract
Objective: To assess a new adenovirus-based immunotherapy as a novel treatment approach to chronic hepatitis B (CHB)., Methods: TG1050 is a non-replicative adenovirus serotype 5 encoding a unique large fusion protein composed of a truncated HBV Core, a modified HBV Polymerase and two HBV Envelope domains. We used a recently described HBV-persistent mouse model based on a recombinant adenovirus-associated virus encoding an over length genome of HBV that induces the chronic production of HBsAg, HBeAg and infectious HBV particles to assess the ability of TG1050 to induce functional T cells in face of a chronic status., Results: In in vitro studies, TG1050 was shown to express the expected large polyprotein together with a dominant, smaller by-product. Following a single administration in mice, TG1050 induced robust, multispecific and long-lasting HBV-specific T cells detectable up to 1 year post-injection. These cells target all three encoded immunogens and display bifunctionality (i.e., capacity to produce both interferon γ and tumour necrosis factor α as well as cytolytic functions). In addition, control of circulating levels of HBV DNA and HBsAg was observed while alanine aminotransferase levels remain in the normal range., Conclusions: Injection of TG1050 induced both splenic and intrahepatic functional T cells producing cytokines and displaying cytolytic activity in HBV-naïve and HBV-persistent mouse models together with significant reduction of circulating viral parameters. These results warrant clinical evaluation of TG1050 in the treatment of CHB., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/)
- Published
- 2015
- Full Text
- View/download PDF
42. HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase.
- Author
-
Rivière L, Gerossier L, Ducroux A, Dion S, Deng Q, Michel ML, Buendia MA, Hantz O, and Neuveut C
- Subjects
- Adaptor Proteins, Signal Transducing metabolism, Blotting, Northern, Blotting, Southern, Cells, Cultured, DNA, Circular metabolism, Enzyme-Linked Immunosorbent Assay, Hepatitis B metabolism, Hepatitis B pathology, Hepatitis B virus metabolism, Histone Methyltransferases, Histone-Lysine N-Methyltransferase metabolism, Humans, Protein Methyltransferases metabolism, Real-Time Polymerase Chain Reaction, Transcription, Genetic, Adaptor Proteins, Signal Transducing genetics, DNA, Circular genetics, DNA, Viral genetics, Hepatitis B genetics, Hepatitis B virus genetics, Histone-Lysine N-Methyltransferase genetics, Protein Methyltransferases genetics
- Abstract
Background & Aims: Maintenance of the covalently closed circular HBV DNA (cccDNA) that serves as a template for HBV transcription is responsible for the failure of antiviral therapies. While studies in chronic hepatitis patients have shown that high viremia correlates with hyperacetylation of cccDNA-associated histones, the molecular mechanisms controlling cccDNA stability and transcriptional regulation are still poorly understood. This study aimed to decipher the role of chromatin and chromatin modifier proteins on HBV transcription., Methods: We analyzed the chromatin structure of actively transcribed or silenced cccDNA by infecting primary human hepatocytes and differentiated HepaRG cells with wild-type virus or virus deficient (HBVX-) for the expression of hepatitis B virus X protein (HBx), that is required for HBV expression., Results: In the absence of HBx, HBV cccDNA was transcriptionally silenced with the concomitant decrease of histone 3 (H3) acetylation and H3K4me3, increase of H3 di- and tri-methylation (H3K9me) and the recruitment of heterochromatin protein 1 factors (HP1) that correlate with condensed chromatin. SETDB1 was found to be the main histone methyltransferase responsible for the deposition of H3K9me3 and HBV repression. Finally, full transcriptional reactivation of HBVX- upon HBx re-expression correlated with an increase of histone acetylation and H3K4me3, and a concomitant decrease of HP1 binding and of H3K9me3 on the cccDNA., Conclusion: Upon HBV infection, cellular mechanisms involving SETDB1-mediated H3K9me3 and HP1 induce silencing of HBV cccDNA transcription through modulation of chromatin structure. HBx is able to relieve this repression and allow the establishment of active chromatin., (Copyright © 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
43. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial.
- Author
-
Rey D, Piroth L, Wendling MJ, Miailhes P, Michel ML, Dufour C, Haour G, Sogni P, Rohel A, Ajana F, Billaud E, Molina JM, Launay O, and Carrat F
- Subjects
- Adult, Aged, Female, France, Hepatitis B Vaccines adverse effects, Humans, Immunization, Secondary adverse effects, Male, Middle Aged, Single-Blind Method, Treatment Outcome, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic adverse effects, Vaccines, Synthetic immunology, Young Adult, HIV Infections immunology, Hepatitis B prevention & control, Hepatitis B Antibodies blood, Hepatitis B Vaccines administration & dosage, Hepatitis B Vaccines immunology, Immunization, Secondary methods
- Abstract
Background: Revaccination with double-dose hepatitis B vaccine has been recommended in HIV-infected patients who do not respond to standard vaccination, but has not yet been assessed. We aimed to compare the safety and immunogenicity of a reinforced hepatitis B revaccination protocol with the standard revaccination schedule in HIV-infected patients not responding to primary vaccination., Methods: We did this multicentre, open-label, randomised controlled trial, at 53 centres in France. HIV-infected adults (aged ≥18 years), with CD4 counts of 200 cells per μL or more and no response to a previous hepatitis B vaccination or a 20 μg booster dose, were randomly assigned (1:1), according to a computer-generated randomisation list with permuted blocks (block sizes of two to six), to receive either standard-dose (20 μg) or double-dose (40 μg) recombinant hepatitis B vaccine at weeks 0, 4, and 24. Randomisation was stratified by baseline CD4 count (200-349 vs ≥350 cells per μL). Patients and treating physicians were not masked to treatment allocation, but the randomisation list was concealed from the investigators who assigned participants to the vaccination groups. The primary endpoint was the proportion of responders, defined as patients with hepatitis B surface antibody (anti-HBs) titres of 10 mIU/mL or more, at week 28. We did analysis by modified intention to treat. This study is registered with ClinicalTrials.gov, number NCT00670839., Findings: Between May 19, 2008, and May 8, 2011, 178 participants were randomly assigned to the standard-dose group (n=90) or the double-dose group (n=88), of whom 176 (98%) participants were included in the primary efficacy analysis. At week 28, we recorded a response in 60 patients (67%, 95% CI 57-77) in the standard-dose group versus 64 patients (74%, 63-82) in the double-dose group (p=0·334). Except for more frequent local reactions in the double-dose group than the standard-dose group (13 [15%] vs four [4%] patients; p=0·020), there was no difference in safety between groups., Interpretation: In adults with HIV-1 who have not responded to previous hepatitis B vaccination, double-dose revaccination did not achieve a higher response rate than did revaccination with standard single-dose regimen. However, the safety profile was similar between treatment groups. Our results should be assessed in future studies before double-dose vaccine can be considered for the standard of care of vaccine non-responders., Funding: French National Institute for Medical Research-French National Agency for Research on AIDS and Viral Hepatitis., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
44. Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes.
- Author
-
Godon O, Evlachev A, Bourgine M, Meritet JF, Martin P, Inchauspe G, and Michel ML
- Subjects
- Adenoviridae genetics, Cross Reactions, Drug Carriers, Epitopes genetics, Genotype, Hepatitis B Core Antigens genetics, Hepatitis B Vaccines genetics, Hepatitis B virus classification, Hepatitis B virus genetics, Humans, Recombinant Fusion Proteins genetics, Vaccines, Synthetic genetics, Vaccines, Synthetic immunology, Epitopes immunology, Hepatitis B Core Antigens immunology, Hepatitis B Vaccines immunology, Hepatitis B virus immunology, Hepatitis B, Chronic therapy, Recombinant Fusion Proteins immunology, T-Lymphocytes immunology
- Abstract
Hepatitis B virus (HBV) infects millions of people worldwide and is a leading cause of liver cirrhosis and hepatocellular carcinoma. Current therapies based on nucleos(t)ide analogs or pegylated-interferon-α lead to control of viral replication in most patients but rarely achieve cure. A potential strategy to control chronic hepatitis B is to restore or induce functional anti-HBV T-cell immune responses using HBV-specific immunotherapeutics. However, viral diversity is a challenge to the development of this class of products as HBV genotypes display a sequence diversity of up to 8%. We have developed a novel HBV-targeted immunotherapeutic, TG1050, based on a non-replicative Adenovirus vector encoding a unique and large fusion protein composed of multiple antigenic regions derived from a HBV genotype D sequence. Using peripheral blood mononuclear cells from 23 patients chronically infected by five distinct genotypes (gt A, B, C, D and E) and various sets of peptides encompassing conserved versus divergent regions of HBV core we have measured ability of TG1050 genotype D core-derived peptides to be recognized by T-cells from patients infected by various genotypes. Overall, PBMCs from 78% of genotype B or C- and 100% genotype A or E-infected patients lead to detection of HBV core-specific T-cells recognizing genotype D antigenic domains located both in conserved and variable regions. This proof-of-concept study supports the clinical development of TG1050 in large patient populations independently of infecting genotypes., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
45. Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure.
- Author
-
Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, Kann M, Knolle PA, Benkirane M, Durantel D, Michel ML, Autran B, Cosset FL, Strick-Marchand H, Trépo C, Kao JH, Carrat F, Lacombe K, Schinazi RF, Barré-Sinoussi F, Delfraissy JF, and Zoulim F
- Subjects
- Disease Progression, Global Health, Humans, Incidence, Antiviral Agents therapeutic use, Carcinoma, Hepatocellular epidemiology, Carcinoma, Hepatocellular etiology, Carcinoma, Hepatocellular prevention & control, DNA, Viral analysis, Hepatitis B virus genetics, Hepatitis B, Chronic complications, Hepatitis B, Chronic drug therapy, Hepatitis B, Chronic virology, Liver Cirrhosis epidemiology, Liver Cirrhosis etiology, Liver Cirrhosis prevention & control, Liver Neoplasms epidemiology, Liver Neoplasms etiology, Liver Neoplasms prevention & control
- Abstract
HBV infection is a major cause of liver cirrhosis and hepatocellular carcinoma. Although HBV infection can be efficiently prevented by vaccination, and treatments are available, to date there is no reliable cure for the >240 million individuals that are chronically infected worldwide. Current treatments can only achieve viral suppression, and lifelong therapy is needed in the majority of infected persons. In the framework of the French National Agency for Research on AIDS and Viral Hepatitis 'HBV Cure' programme, a scientific workshop was held in Paris in June 2014 to define the state-of-the-art and unanswered questions regarding HBV pathobiology, and to develop a concerted strategy towards an HBV cure. This review summarises our current understanding of HBV host-interactions leading to viral persistence, as well as the roadblocks to be overcome to ultimately address unmet medical needs in the treatment of chronic HBV infection., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.)
- Published
- 2015
- Full Text
- View/download PDF
46. Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end?
- Author
-
Michel ML, Bourgine M, Fontaine H, and Pol S
- Subjects
- Clinical Trials as Topic, Hepatitis B, Chronic immunology, Humans, Treatment Outcome, Hepatitis B Vaccines therapeutic use, Hepatitis B, Chronic therapy, Immunotherapy methods
- Abstract
The antiviral treatment of chronic hepatitis B virus (HBV) infection has greatly improved over the last 20 years since it has allowed a disappearance of cirrhosis decompensation and a significant reduction of the incidence of hepatocellular carcinoma. However, a complete HBV cure has not been achieved, and alternative treatments are still needed to optimize the current treatments. Therapeutic vaccination is a promising new strategy for controlling persistent infections and tumors. However, this approach has not been as successful as initially anticipated for chronic hepatitis B. General impairment of the immune responses generated during persistent HBV infection, with exhausted T cells not responding correctly to therapeutic vaccination, is most likely responsible for the poor clinical responses observed to date. We describe here the past approaches of therapeutic vaccination, in the hope that useful lessons will emerge from these previous clinical trials. Intensive research efforts are now focusing on a better understanding of immune responses in liver, on mechanisms by which HBV escapes innate immunity and on an accurate selection of the patients susceptible to benefit of immune therapy, which could increase the efficacy of therapeutic vaccination.
- Published
- 2015
- Full Text
- View/download PDF
47. Minicircle: Next Generation DNA Vectors for Vaccination.
- Author
-
Schleef M, Schirmbeck R, Reiser M, Michel ML, and Schmeer M
- Subjects
- Animals, Electrophoresis, Agar Gel, Electrophoresis, Capillary, Mice, Inbred C57BL, Plasmids metabolism, DNA, Circular metabolism, Genetic Vectors metabolism, Vaccination methods
- Abstract
The use of DNA vaccines requires pharmaceutical grade DNA that causes the immunization on the basis of a nucleic acid sequence that encodes the protein to be vaccinated against. This nucleic acid sequence can be a circular or linear plasmid, preferably a double stranded one and should not contain any other and especially not any "toxic" sequences. Sequences that are not desirable to be part of the DNA drug can be those deriving from the (typically) bacterial amplification system to produce the DNA vaccine. These could be those portions of a plasmid that are only used for controlling the bacterial replication of the plasmid or those used to select for the plasmid during cloning or even worse during production. After initial approaches to avoid the presence of these sequences in DNA vaccine plasmids with "mini-plasmids," a significant improvement in product safety was obtained by use of minicircles-circular and ccc-supercoiled expression cassettes of the DNA vaccine. Initial results proofed their extremely high expression level and recent comparison of DNA vaccines based on either plasmid or minicircle DNA show successful vaccination against HBV in mice, as shown in this overview chapter.
- Published
- 2015
- Full Text
- View/download PDF
48. Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN.
- Author
-
Fontaine H, Kahi S, Chazallon C, Bourgine M, Varaut A, Buffet C, Godon O, Meritet JF, Saïdi Y, Michel ML, Scott-Algara D, Aboulker JP, and Pol S
- Subjects
- Adult, Antiviral Agents therapeutic use, Female, Humans, Male, Middle Aged, Prospective Studies, Recurrence, Treatment Failure, Hepatitis B Vaccines, Hepatitis B, Chronic prevention & control, Vaccines, DNA
- Abstract
Objective: The antiviral efficacy of nucleos(t)ide analogues whose main limitation is relapse after discontinuation requires long-term therapy. To overcome the risk of relapse and virological breakthrough during long-term therapy, we performed a phase I/II, open, prospective, multicentre trial using a HBV envelope-expressing DNA vaccine., Design: 70 patients treated effectively with nucleos(t)ide analogues for a median of 3 years (HBV DNA <12 IU/mL for at least 12 months) were randomised into two groups: one received five intramuscular injections of vaccine (weeks 0, 8, 16, 40 and 44) and one did not receive the vaccine. Analogues were stopped after an additional 48 weeks of treatment in patients who maintained HBV DNA <12 IU/mL with no clinical progression and monthly HBV DNA for 6 months. The primary endpoint was defined as viral reactivation at week 72 (HBV DNA >120 IU/mL) or impossibility of stopping treatment at week 48., Results: Reactivation occurred in 97% of each group after a median 28 days without liver failure but with an HBV DNA <2000 IU/mL in 33%; 99% of adverse reactions were mild to moderate. Immune responses were evaluated by enzyme-linked immunosorbent spot and proliferation assays: there was no difference in the percentage of patients with interferon-γ secreting cells and a specific T-cell proliferation to HBcAg but not to HBsAg after reactivation in each group., Conclusions: Although it is fairly well tolerated, the HBV DNA vaccine does not decrease the risk of relapse in HBV-treated patients or the rate of virological breakthrough, and does not restore the anti-HBV immune response despite effective viral suppression by analogues., Trial Registration Number: NCT00536627., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.)
- Published
- 2015
- Full Text
- View/download PDF
49. Interleukin-8 (CXCL8) production is a signatory T cell effector function of human newborn infants.
- Author
-
Gibbons D, Fleming P, Virasami A, Michel ML, Sebire NJ, Costeloe K, Carr R, Klein N, and Hayday A
- Subjects
- Adult, Animals, Animals, Newborn, Cytokines biosynthesis, Cytokines blood, Female, Fetal Blood immunology, Humans, Infant, Newborn blood, Infant, Premature blood, Infant, Premature immunology, Interleukin-8 blood, Interleukin-8 genetics, Lymphocyte Activation, Male, Mice, Mice, Inbred C57BL, Th1 Cells immunology, Th17 Cells immunology, Th2 Cells immunology, Infant, Newborn immunology, Interleukin-8 biosynthesis, T-Lymphocyte Subsets immunology
- Abstract
In spite of their precipitous encounter with the environment, newborn infants cannot readily mount T helper type 1 (TH1) cell antibacterial and antiviral responses. Instead, they show skewing toward TH2 responses, which, together with immunoregulatory functions, are thought to limit the potential for inflammatory damage, while simultaneously permitting intestinal colonization by commensals. However, these collective capabilities account for relatively few T cells. Here we demonstrate that a major T cell effector function in human newborns is interleukin-8 (CXCL8) production, which has the potential to activate antimicrobial neutrophils and γδ T cells. CXCL8 production was provoked by antigen receptor engagement of T cells that are distinct from those few cells producing TH1, TH2 and TH17 cytokines, was co-stimulated by Toll-like receptor signaling, and was readily apparent in preterm babies, particularly those experiencing neonatal infections and severe pathology. By contrast, CXCL8-producing T cells were rare in adults, and no equivalent function was evident in neonatal mice. CXCL8 production counters the widely held view that T lymphocytes in very early life are intrinsically anti-inflammatory, with implications for immune monitoring, immune interventions (including vaccination) and immunopathologies. It also emphasizes qualitative distinctions between infants' and adults' immune systems.
- Published
- 2014
- Full Text
- View/download PDF
50. Human hematopoietic reconstitution and HLA-restricted responses in nonpermissive alymphoid mice.
- Author
-
Serra-Hassoun M, Bourgine M, Boniotto M, Berges J, Langa F, Michel ML, Freitas AA, and Garcia S
- Subjects
- Animals, Animals, Newborn, Antigens, Differentiation administration & dosage, Antigens, Differentiation blood, Antigens, Differentiation genetics, Cell Survival genetics, Cell Survival immunology, Disease Models, Animal, Female, HLA Antigens genetics, Humans, Mice, Mice, 129 Strain, Mice, Inbred C57BL, Mice, Inbred NOD, Mice, Knockout, Mice, SCID, Mice, Transgenic, Organ Culture Techniques, Radiation Chimera genetics, Receptors, Immunologic administration & dosage, Receptors, Immunologic blood, Receptors, Immunologic genetics, HLA Antigens administration & dosage, HLA Antigens immunology, Hematopoietic Stem Cell Transplantation methods, Radiation Chimera immunology
- Abstract
We generated a new humanized mouse model to study HLA-restricted immune responses. For this purpose, we created unique murine hosts by enforcing the expression of human SIRPα by murine phagocytes in murine MHC-deficient HLA-transgenic alymphoid hosts, an approach that allowed the immune reconstitution of nonpermissive mice following injection of human hematopoietic stem cells. We showed that these mouse/human chimeras were able to generate HLA-restricted responses to immunization. These new humanized mice may offer attractive models to study immune responses to human diseases, such as HIV and EBV infections, as well as to assay new vaccine strategies., (Copyright © 2014 by The American Association of Immunologists, Inc.)
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.